Search

Your search keyword '"Di Bartolomeo, Maria"' showing total 737 results
Start Over Author "Di Bartolomeo, Maria"
737 results on '"Di Bartolomeo, Maria"'

1. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape: Bertinoro Workshop, November 2022

Author

Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han-Kwang, Roviello, Franco, and de Manzoni, Giovanni

Published
2024
Full Text
View/download PDF

2. Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape

Author

Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han-Kwang, Roviello, Franco, and de Manzoni, Giovanni

Published
2024
Full Text
View/download PDF

3. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Author

Siena, Salvatore, Raghav, Kanwal, Masuishi, Toshiki, Yamaguchi, Kensei, Nishina, Tomohiro, Elez, Elena, Rodriguez, Javier, Chau, Ian, Di Bartolomeo, Maria, Kawakami, Hisato, Suto, Fumitaka, Koga, Makito, Inaki, Koichiro, Kuwahara, Yusuke, Takehara, Issey, Barrios, Daniel, Kobayashi, Kojiro, Grothey, Axel, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

4. Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Rafaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

5. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Raffaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

6. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

Author

Kang, Yoon-Koo, Ryu, Min-Hee, Di Bartolomeo, Maria, Chau, Ian, Yoon, Harry, Kim, Jong Gwang, Lee, Keun-Wook, Oh, Sang Chul, Takashima, Atsuo, Kryzhanivska, Anna, Chao, Yee, Evesque, Ludovic, Schenker, Michael, McGinn, Arlo, Zhao, Yufan, Lee, Jennifer, Wyrwicz, Lucjan, and Boku, Narikazu

Published
2024
Full Text
View/download PDF

7. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Author

Van Cutsem, Eric, di Bartolomeo, Maria, Smyth, Elizabeth, Chau, Ian, Park, Haeseong, Siena, Salvatore, Lonardi, Sara, Wainberg, Zev, Ajani, Jaffer, Chao, Joseph, Janjigian, Yelena, Qin, Amy, Singh, Jasmeet, Barlaskar, Ferdous, Kawaguchi, Yoshinori, and Ku, Geoffrey

Subjects
Female, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Esophageal Neoplasms, Esophagogastric Junction, Immunoconjugates, Receptor, ErbB-2, Stomach Neoplasms, Trastuzumab, Aged
Abstract

BACKGROUND: Approximately 15-20% of advanced gastric and gastro-oesophageal junction cancers overexpress HER2. In DESTINY-Gastric01, the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan improved response and overall survival versus chemotherapy in patients from Japan and South Korea with locally advanced or metastatic HER2-positive gastric or gastro-oesophageal junction cancer whose disease progressed after two lines of previous therapy including trastuzumab. Here, we report primary and updated analyses of the single-arm, phase 2 DESTINY-Gastric02 trial, which aimed to examine trastuzumab deruxtecan in patients living in the USA and Europe. METHODS: DESTINY-Gastric02 is a single-arm, phase 2 study in adult patients from 24 study sites in the USA and Europe (Belgium, Spain, Italy, and the UK). Eligible patients were aged at least 18 years and had an Eastern Cooperative Oncology Group performance status of 0 or 1, pathologically documented unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen, with at least one measurable lesion per Response Evaluation Criteria in Solid Tumours (version 1.1), and centrally confirmed HER2-positive disease on a postprogression biopsy. Patients were given 6·4 mg/kg of trastuzumab deruxtecan intravenously every 3 weeks until disease progression, withdrawal by patient, physician decision, or death. The primary endpoint was confirmed objective response rate by independent central review. The primary endpoint and safety were assessed in the full analysis set (ie, participants who received at least one dose of study drug). Here, we report the primary analysis of this study, with a data cutoff of April 9, 2021, and an updated analysis, with a data cutoff of Nov 8, 2021. This trial is registered with ClinicalTrials.gov, NCT04014075, and is ongoing. FINDINGS: Between Nov 26, 2019, and Dec 2, 2020, 89 patients were screened and 79 were enrolled and subsequently treated with trastuzumab deruxtecan (median age 60·7 years [IQR 52·0-68·3], 57 [72%] of 79 were male, 22 [28%] were female, 69 [87%] were White, four [5%] were Asian, one [1%] was Black or African American, one [1%] was Native Hawaiian or Pacific Islander, one had missing race, and three [4%] were other races). At the primary analysis (median follow-up 5·9 months [IQR 4·6-8·6 months]), confirmed objective response was reported in 30 (38% [95% CI 27·3-49·6]) of 79 patients, including three (4%) complete responses and 27 (34%) partial responses, as assessed by independent central review. As of data cutoff for the updated analysis (median follow-up 10·2 months [IQR 5·6-12·9]), a confirmed objective response was reported in 33 (42% [95% CI 30·8-53·4]) of 79 patients, including four (5%) complete responses and 29 (37%) partial responses, as assessed by independent central review. The most common grade 3 or worse treatment-emergent adverse events were anaemia (11 [14%]), nausea (six [8%]), decreased neutrophil count (six [8%]), and decreased white blood cell count (five [6%]). Drug-related serious treatment-emergent adverse events occurred in ten patients (13%). Deaths determined to be associated with study treatment occurred in two patients (3%) and were due to interstitial lung disease or pneumonitis. INTERPRETATION: These clinically meaningful results support the use of trastuzumab deruxtecan as second-line therapy in patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. FUNDING: Daiichi Sankyo and AstraZeneca.

Published
2023

8. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.

Author

Shitara, Kohei, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Caglevic, Christian, Olesinski, Tomasz, Chung, Hyun, Muro, Kei, Goekkurt, Eray, McDermott, Raymond, Mansoor, Wasat, Shih, Chie-Schin, Kobie, Julie, Nebozhyn, Michael, Cristescu, Razvan, Cao, Z, Loboda, Andrey, Özgüroğlu, Mustafa, and Wainberg, Zev

Subjects
Gastrointestinal Neoplasms, Gene Expression Profiling, Genetic Markers, Immunotherapy, Programmed Cell Death 1 Receptor, Humans, Paclitaxel, Stomach Neoplasms, Transcriptome, Antibodies, Monoclonal, Humanized
Abstract

BACKGROUND: In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but did elicit a longer duration of response and offered a favorable safety profile. This prespecified exploratory analysis was conducted to evaluate associations between tumor gene expression signatures and clinical outcomes in the phase III KEYNOTE-061 trial. METHODS: Using RNA sequencing data obtained from formalin-fixed, paraffin-embedded baseline tumor tissue samples, we evaluated the 18-gene T-cell-inflamed gene expression profile (TcellinfGEP) and 10 non-TcellinfGEP signatures (angiogenesis, glycolysis, granulocytic myeloid-derived suppressor cell (gMDSC), hypoxia, monocytic MDSC (mMDSC), MYC, proliferation, RAS, stroma/epithelial-to-mesenchymal transition/transforming growth factor-β, WNT). The association between each signature on a continuous scale and outcomes was analyzed using logistic (objective response rate (ORR)) and Cox proportional hazards regression (progression-free survival (PFS) and OS). One-sided (pembrolizumab) and two-sided (paclitaxel) p values were calculated for TcellinfGEP (prespecified α=0.05) and the 10 non-TcellinfGEP signatures (multiplicity-adjusted; prespecified α=0.10). RESULTS: RNA sequencing data were available for 137 patients in each treatment group. TcellinfGEP was positively associated with ORR (p=0.041) and PFS (p=0.026) for pembrolizumab but not paclitaxel (p>0.05). The TcellinfGEP-adjusted mMDSC signature was negatively associated with ORR (p=0.077), PFS (p=0.057), and OS (p=0.033) for pembrolizumab, while the TcellinfGEP-adjusted glycolysis (p=0.018), MYC (p=0.057), and proliferation (p=0.002) signatures were negatively associated with OS for paclitaxel. CONCLUSIONS: This exploratory analysis of tumor TcellinfGEP showed associations with ORR and PFS for pembrolizumab but not for paclitaxel. TcellinfGEP-adjusted mMDSC signature was negatively associated with ORR, PFS, and OS for pembrolizumab but not paclitaxel. These data suggest myeloid-driven suppression may play a role in resistance to PD-1 inhibition in G/GEJ cancer and support a strategy of considering immunotherapy combinations which target this myeloid axis. TRIAL REGISTRATION NUMBER: NCT02370498.

Published
2023

9. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Author

Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev, Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore, and DESTINY-CRC01 investigators

Subjects
DESTINY-CRC01 investigators, Humans, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Camptothecin, Receptor, erbB-2, Immunoconjugates, Female, Antibodies, Monoclonal, Humanized, Trastuzumab, Receptor, ErbB-2, Clinical Research, Clinical Trials and Supportive Activities, Colo-Rectal Cancer, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals
Abstract

DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.

Published
2023

11. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

Author

Corti, Francesca, Brizzi, Maria Pia, Amoroso, Vito, Giuffrida, Dario, Panzuto, Francesco, Campana, Davide, Prinzi, Natalie, Milione, Massimo, Cascella, Tommaso, Spreafico, Carlo, Randon, Giovanni, Oldani, Simone, Leporati, Rita, Scotto, Giulia, Pulice, Iolanda, Stocchetti, Benedetta Lombardi, Porcu, Luca, Coppa, Jorgelina, Di Bartolomeo, Maria, de Braud, Filippo, and Pusceddu, Sara

Published
2023
Full Text
View/download PDF

12. ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series

Author

Ambrosini, Margherita, Del Re, Marzia, Manca, Paolo, Hendifar, Andrew, Drilon, Alexander, Harada, Guilherme, Ree, Anne Hansen, Klempner, Samuel, Mælandsmo, Gunhild Mari, Flatmark, Kjersti, Russnes, Hege G, Cleary, James M, Singh, Harshabad, Sottotetti, Elisa, Martinetti, Antonia, Randon, Giovanni, Sartore-Bianchi, Andrea, Capone, Iolanda, Milione, Massimo, Di Bartolomeo, Maria, and Pietrantonio, Filippo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Rare Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Carcinoma, Non-Small-Cell Lung, Crizotinib, Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Prospective Studies, Protein Kinase Inhibitors, Oncology and carcinogenesis
Abstract

PurposeIn GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non-small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarce.Materials and methodsWe assembled a clinical and molecular international data set of pretreated patients with metastatic or nonresectable cancers of GI primary tumor origin with documented ALK rearrangement treated with at least one line of ALKi. Measurable disease as per RECIST 1.1 was required for response analysis.ResultsPrimary tumor sites were distributed as follows: 5 (38%) pancreas, 3 (23%) right colon, and 1 (8%) for each one of gastric, duodenal, rectal, left colon, and biliary tract sites. Seven patients (54%) were treated with alectinib, 5 (38%) with crizotinib, and 1 (8%) with entrectinib. After disease progression, five patients (38%) received a subsequent ALKi treatment line, and at the time of data cutoff date, treatment was still ongoing in two patients. Five of 12 evaluable patients (41%) achieved a partial response to first-line ALKi, five patients (41%) had stable disease, and 2 (17%) had progressive disease. No complete responses were registered. At a median follow-up of 39.6 months (interquartile range: 19.8-59.5), the median progression-free survival was 5.0 months (95% CI, 3.68 to no response) and the median overall survival was 9.3 months (95% CI, 5.46 to no response).ConclusionTreatment with ALKi provides remarkable responses and clinical benefit in pretreated patients with ALK fusion-positive GI malignancies. Despite the rarity, ALK rearrangements represent an important therapeutic target in individual pretreated patients with GI solid tumors. Further work providing prospective clinical validation of this target is needed.

Published
2022

14. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Author

Shitara, Kohei, Rha, Sun Young, Wyrwicz, Lucjan S, Oshima, Takashi, Karaseva, Nina, Osipov, Mikhail, Yasui, Hisateru, Yabusaki, Hiroshi, Afanasyev, Sergey, Park, Young-Kyu, Al-Batran, Salah-Eddin, Yoshikawa, Takaki, Yanez, Patricio, Di Bartolomeo, Maria, Lonardi, Sara, Tabernero, Josep, Van Cutsem, Eric, Janjigian, Yelena Y, Oh, Do-Youn, Xu, Jianming, Fang, Xiao, Shih, Chie-Schin, Bhagia, Pooja, and Bang, Yung-Jue

Published
2024
Full Text
View/download PDF

15. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin

Author

Ghelardi, Filippo, Raimondi, Alessandra, Morano, Federica, Randon, Giovanni, Pannone, Alessandra, Guaglio, Marcello, Mazzoli, Giacomo, Nasca, Vincenzo, Milione, Massimo, Leoncini, Giuseppe, Sabella, Giovanna, Greco, Gabriella Francesca, Lampis, Bianca Rosa, Galassi, Margherita, Delfanti, Sara, Nannini, Margherita, Intini, Rossana, Baratti, Dario, Di Bartolomeo, Maria, Deraco, Marcello, and Pietrantonio, Filippo

Published
2023
Full Text
View/download PDF

16. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

18. Tumors of the Small Intestine, Colon, and Rectum

Author

Signoroni, Stefano, Di Bartolomeo, Maria, Ferrari, Andrea, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor

Published
2022
Full Text
View/download PDF

19. Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

Author

Pietrantonio, Filippo, primary, Randon, Giovanni, additional, Lonardi, Sara, additional, Garattini, Silvio Ken, additional, Tamberi, Stefano, additional, Giommoni, Elisa, additional, Di Donato, Samantha, additional, Fornaro, Lorenzo, additional, Brunetti, Oronzo, additional, De Vita, Ferdinando, additional, Frassineti, Giovanni Luca, additional, Chini, Claudio, additional, Spallanzani, Andrea, additional, Bethaz, Valerie, additional, Strippoli, Antonia, additional, Latiano, Tiziana Pia, additional, Cardellino, Giovanni Gerardo, additional, Palermo, Federica, additional, Miceli, Rosalba, additional, and Di Bartolomeo, Maria, additional

Published
2024
Full Text
View/download PDF

20. Translating knowledge into policy: Organizational model and minimum requirements for the implementation of a regional pancreas unit network

Author

Balzano, Gianpaolo, primary, Reni, Michele, additional, Di Bartolomeo, Maria, additional, Scorsetti, Marta, additional, Caraceni, Augusto, additional, Rivizzigno, Piero, additional, Amorosi, Alessandro, additional, Scardoni, Alessandro, additional, Abu Hilal, Mohammad, additional, Ferrari, Giovanni, additional, Labianca, Roberto, additional, Venturini, Massimo, additional, Doglioni, Claudio, additional, Riva, Luca, additional, Caccialanza, Riccardo, additional, and Carrara, Silvia, additional

Published
2024
Full Text
View/download PDF

22. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Author

Fuchs, Charles S., Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesinski, Tomasz, Caglevic, Christian, Chung, Hyun C., Muro, Kei, Van Cutsem, Eric, Elme, Anneli, Thuss-Patience, Peter, Chau, Ian, Ohtsu, Atsushi, Bhagia, Pooja, Wang, Anran, Shih, Chie-Schin, and Shitara, Kohei

Published
2022
Full Text
View/download PDF

23. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Author

Kato, Ken, primary, Doki, Yuichiro, additional, Chau, Ian, additional, Xu, Jianming, additional, Wyrwicz, Lucjan, additional, Motoyama, Satoru, additional, Ogata, Takashi, additional, Kawakami, Hisato, additional, Hsu, Chih‐Hung, additional, Adenis, Antoine, additional, El Hajbi, Farid, additional, Di Bartolomeo, Maria, additional, Braghiroli, Maria Ignez, additional, Holtved, Eva, additional, Makino, Tomoki, additional, Blum Murphy, Mariela, additional, Amaya‐Chanaga, Carlos, additional, Patel, Apurva, additional, Hu, Nan, additional, Matsumura, Yasuhiro, additional, Kitagawa, Yuko, additional, and Ajani, Jaffer, additional

Published
2024
Full Text
View/download PDF

24. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Author

Siena, Salvatore, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Fakih, Marwan, Elez, Elena, Rodriguez, Javier, Ciardiello, Fortunato, Komatsu, Yoshito, Esaki, Taito, Chung, Ki, Wainberg, Zev, Sartore-Bianchi, Andrea, Saxena, Kapil, Yamamoto, Eriko, Bako, Emarjola, Okuda, Yasuyuki, Shahidi, Javad, Grothey, Axel, and Yoshino, Takayuki

Published
2021
Full Text
View/download PDF

25. Recent Advances in the Management of Typical and Atypical Lung Carcinoids

Author

Prinzi, Natalie, Rossi, Roberta Elisa, Proto, Claudia, Leuzzi, Giovanni, Raimondi, Alessandra, Torchio, Martina, Milione, Massimo, Corti, Francesca, Colombo, Elena, Prisciandaro, Michele, Cascella, Tommaso, Spreafico, Carlo, Beninato, Teresa, Coppa, Jorgelina, Lo Russo, Giuseppe, Di Bartolomeo, Maria, de Braud, Filippo, and Pusceddu, Sara

Published
2021
Full Text
View/download PDF

26. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study

Author

Raimondi, Alessandra, Corallo, Salvatore, Lonardi, Sara, Antoniotti, Carlotta, Rimassa, Lorenza, Amatu, Alessio, Tampellini, Marco, Racca, Patrizia, Murialdo, Roberto, Clavarezza, Matteo, Zaniboni, Alberto, Toscano, Giuseppe, Tomasello, Gianluca, Petrelli, Fausto, Antonuzzo, Lorenzo, Giordano, Monica, Cinieri, Saverio, Longarini, Raffaella, Niger, Monica, Antista, Maria, Ambrosini, Margherita, Pagani, Filippo, Prisciandaro, Michele, Randon, Giovanni, de Braud, Filippo, Di Bartolomeo, Maria, Pietrantonio, Filippo, and Morano, Federica

Published
2021
Full Text
View/download PDF

27. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

Author

Alyami, Mohammad S., André, Thierry, Barrios-Sanchez, Pedro, Baumgartner, Joel M., Bhatt, Aditi, Ben-Yaacov, Almog, Bertulli, Rosella, Braess, Jan, Burger, Jacobus W.A., Cascales-Campos, Pedro, Cashin, Peter, Cecil, P, Tom, Ceelen, Wim P., Creemers, Geert-Jan, Cortes-Guiral, Delia, Dayal, Sanjeev, De Simone, Michele, Di Bartolomeo, Maria, Dube, Pierre, Flatmark, Kjersti, Foster, Jason M., Goere, Diane, Gonzales-Bayon, Luis, Heriot, Alexander, Hewett, Peter J., Hsieh, Mao-Chih, Hubner, Martin, Kok, NielsF.M., Larsen, Stein G., Lehmann, Kuno, Li, Yan, Loggie, Brian W., Lutton, Nicholas, Ly, Jasen, Lynch, Craig, Lyra, Marcos, Mehta, Sanket, Mohamed, Faheez, Morris, David L., Nissan, Aviram, Nowacki, Maciej S., Pande, Pankaj K., Park, Eun Jung, Peron, Julien, Perry, David J., Pietrantonio, Filippo, Piso, Pompiliu, Pocard, Marc, Quadros, Claudio, Rajan, Firoz, Rau, Beate, Reymond, Marc A., Thuss-Patience, Peter, Sardi, Armando, Sideris, Lucas, Sinn, Marianne, Sokmen, Selman, Somashekhar, Sampige P., Spiliotis, John D., Sugarbaker, Paul H., Syk, Ingvar, Tentes, Antonios A., Teo, MelissaC.C., Turaga, Kiran K., Valle, Mario, Verwaal, Victor J., Wilson, Malcom S., Yarema, Roman R., Yonemura, Yutaka, Yu, Yang, Lurvink, R.J., Villeneuve, L., Govaerts, K., de Hingh, I.H.J.T., Moran, B.J., Deraco, M., Van der Speeten, K., Glehen, O., Kepenekian, V., and Kusamura, S.

Published
2021
Full Text
View/download PDF

28. Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024) 27 4 DOI: 10.1007/s10120-024-01479-5)

Author

MS CGO, Cancer, Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han Kwang, Roviello, Franco, de Manzoni, Giovanni, Bertinoro Workshop Working Group, MS CGO, Cancer, Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han Kwang, Roviello, Franco, de Manzoni, Giovanni, and Bertinoro Workshop Working Group

Published
2024

29. International consensus on the management of metastatic gastric cancer:step by step in the foggy landscape

Author

Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han Kwang, Roviello, Franco, de Manzoni, Giovanni, Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han Kwang, Roviello, Franco, and de Manzoni, Giovanni

Abstract

Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible. Methods: A two-round Delphi process was carried out, where participants were asked to answer 32 multiple-choice questions about CT, laparoscopic staging and biomarkers, systemic treatment for different localization, role and indication of palliative care. Consensus was established with at least a 67% agreement. Results: The assembly agreed to define oligometastases as a “dynamic” disease which either regresses or remains stable in response to systemic treatment. In addition, the definition of oligometastases was restricted to the following sites: para-aortic nodal stations, liver, lung, and peritoneum, excluding bones. In detail, the following conditions should be considered as oligometastases: involvement of para-aortic stations, in particular 16a2 or 16b1; up to three technically resectable liver metastases; three unilateral or two bilateral lung metastases; peritoneal carcinomatosis with PCI ≤ 6. No consensus was achieved on how to classify positive cytology, which was considered as oligometastatic by 55% of participants only if converted to negative after chemotherapy. Conclusion: As assessed at the time of diagnosis, surgical treatment of oligometastases should aim at R0 curativity on the entire disease volume, including both the primary tumor and its metastases. Conversion surgery was defined as surgery on the residual volume of disease, which was initially not resectable for technical and/or oncological reasons but nevertheles

Published
2024

31. Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.

Author

Lei, Ming, primary, Doki, Yuichiro, additional, Kitagawa, Yuko, additional, Kato, Ken, additional, Chau, Ian, additional, Yao, Jin, additional, Xu, Jianming, additional, Wyrwicz, Lucjan S., additional, Motoyama, Satoru, additional, Ogata, Takashi, additional, Kawakami, Hisato, additional, Hsu, Chih-Hung, additional, Adenis, Antoine, additional, El Hajbi, Farid, additional, Di Bartolomeo, Maria, additional, Braghiroli, Maria Ignez, additional, Holtved, Eva, additional, Blum Murphy, Mariela A., additional, Novosiadly, Ruslan, additional, and Ajani, Jaffer A., additional

Published
2024
Full Text
View/download PDF

32. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer

Author

Nichetti, Federico, primary, Rota, Simone, additional, Ambrosini, Paolo, additional, Pircher, Chiara, additional, Gusmaroli, Eleonora, additional, Droz Dit Busset, Michele, additional, Pusceddu, Sara, additional, Sposito, Carlo, additional, Coppa, Jorgelina, additional, Morano, Federica, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, Mariani, Luigi, additional, Mazzaferro, Vincenzo, additional, de Braud, Filippo, additional, and Niger, Monica, additional

Published
2024
Full Text
View/download PDF

35. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab

Author

Ruzzo, Annamaria, Graziano, Francesco, Bagaloni, Irene, Di Bartolomeo, Maria, Prisciandaro, Michele, Aprile, Giuseppe, Ongaro, Elena, Vincenzi, Bruno, Perrone, Giuseppe, Santini, Daniele, Fornaro, Lorenzo, Vivaldi, Caterina, Tomasello, Gianluca, Loupakis, Fotios, Lonardi, Sara, Fassan, Matteo, Valmasoni, Michele, Sarti, Donatella, Lorenzini, Paola, Catalano, Vincenzo, Bisonni, Renato, Del Prete, Michela, Collina, Guido, and Magnani, Mauro

Published
2020
Full Text
View/download PDF

37. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Ahn, JB, Asselah, J, Badarinath, S, Baijal, S, Begbie, S, Berry, S, Canon, JL, Carbone, RG, Cervantes, A, Cha, YJ, Chang, K, Chaudhry, A, Chmielowska, E, Cho, SH, Chu, D, Couture, F, Cultrera, J, Cunningham, D, Van Cutsem, E, Cuyle, PJ, Davies, J, Dowden, S, Dvorkin, M, Ganju, V, Garcia, RV, Kerr, R, Kim, TY, King, K, Kortmansky, J, Kozloff, M, Lam, KO, Lee, J, Lee, AS, Lesperance, B, Luppi, G, Ma, B, Maiello, E, Mandanas, R, Marshall, J, Marx, G, Mullamitha, S, Nechaeva, M, Park, JO, Pavlakis, N, Ponce, CG, Potemski, P, Raouf, S, Reeves, J, Segal, N, Siena, S, Smolin, A, Streb, JO, Strickland, A, Szutowicz-Zielinska, E, Tabernero, JM, Tan, B, Valera, JS, Van den Eynde, M, Vergauwe, P, Vickers, M, Womack, M, Wroblewska, M, Young, R, Eng, Cathy, Kim, Tae Won, Bendell, Johanna, Argilés, Guillem, Tebbutt, Niall C, Di Bartolomeo, Maria, Falcone, Alfredo, Fakih, Marwan, Kozloff, Mark, Segal, Neil H, Sobrero, Alberto, Yan, Yibing, Chang, Ilsung, Uyei, Anne, Roberts, Louise, and Ciardiello, Fortunato

Published
2019
Full Text
View/download PDF

38. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

39. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional

Published
2023
Full Text
View/download PDF

44. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Author

Di Bartolomeo, Maria, Niger, Monica, Tirino, Giuseppe, Petrillo, Angelica, Berenato, Rosa, Laterza, Maria Maddalena, Pietrantonio, Filippo, Morano, Federica, Antista, Maria, Lonardi, Sara, Fornaro, Lorenzo, Tamberi, Stefano, Giommoni, Elisa, Zaniboni, Alberto, Rimassa, Lorenza, Tomasello, Gianluca, Sava, Teodoro, Spada, Massimiliano, Latiano, Tiziana, Bittoni, Alessandro, Bertolini, Alessandro, Proserpio, Ilaria, Bencardino, Katia Bruna, Graziano, Francesco, Beretta, Giordano, Galdy, Salvatore, Ventriglia, Jole, Scagnoli, Simone, Spallanzani, Andrea, Longarini, Raffaella, and De Vita, Ferdinando

Published
2018
Full Text
View/download PDF

45. Data from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

Author

Pietrantonio, Filippo, primary, Oddo, Daniele, primary, Gloghini, Annunziata, primary, Valtorta, Emanuele, primary, Berenato, Rosa, primary, Barault, Ludovic, primary, Caporale, Marta, primary, Busico, Adele, primary, Morano, Federica, primary, Gualeni, Ambra Vittoria, primary, Alessi, Alessandra, primary, Siravegna, Giulia, primary, Perrone, Federica, primary, Di Bartolomeo, Maria, primary, Bardelli, Alberto, primary, de Braud, Filippo, primary, and Di Nicolantonio, Federica, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figures S1 - S3 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

Author

Pietrantonio, Filippo, primary, Oddo, Daniele, primary, Gloghini, Annunziata, primary, Valtorta, Emanuele, primary, Berenato, Rosa, primary, Barault, Ludovic, primary, Caporale, Marta, primary, Busico, Adele, primary, Morano, Federica, primary, Gualeni, Ambra Vittoria, primary, Alessi, Alessandra, primary, Siravegna, Giulia, primary, Perrone, Federica, primary, Di Bartolomeo, Maria, primary, Bardelli, Alberto, primary, de Braud, Filippo, primary, and Di Nicolantonio, Federica, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

Author

Pietrantonio, Filippo, primary, Oddo, Daniele, primary, Gloghini, Annunziata, primary, Valtorta, Emanuele, primary, Berenato, Rosa, primary, Barault, Ludovic, primary, Caporale, Marta, primary, Busico, Adele, primary, Morano, Federica, primary, Gualeni, Ambra Vittoria, primary, Alessi, Alessandra, primary, Siravegna, Giulia, primary, Perrone, Federica, primary, Di Bartolomeo, Maria, primary, Bardelli, Alberto, primary, de Braud, Filippo, primary, and Di Nicolantonio, Federica, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

Author

Pietrantonio, Filippo, primary, Oddo, Daniele, primary, Gloghini, Annunziata, primary, Valtorta, Emanuele, primary, Berenato, Rosa, primary, Barault, Ludovic, primary, Caporale, Marta, primary, Busico, Adele, primary, Morano, Federica, primary, Gualeni, Ambra Vittoria, primary, Alessi, Alessandra, primary, Siravegna, Giulia, primary, Perrone, Federica, primary, Di Bartolomeo, Maria, primary, Bardelli, Alberto, primary, de Braud, Filippo, primary, and Di Nicolantonio, Federica, primary

Published
2023
Full Text
View/download PDF

49. Figure S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Author

Pietrantonio, Filippo, primary, Manca, Paolo, primary, Bellomo, Sara Erika, primary, Corso, Simona, primary, Raimondi, Alessandra, primary, Berrino, Enrico, primary, Morano, Federica, primary, Migliore, Cristina, primary, Niger, Monica, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella Maria, primary, Marchiò, Caterina, primary, Di Bartolomeo, Maria, primary, Restuccia, Eleonora, primary, Lambertini, Chiara, primary, Tabernero, Josep, primary, and Giordano, Silvia, primary

Published
2023
Full Text
View/download PDF

50. Table S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Author

Pietrantonio, Filippo, primary, Manca, Paolo, primary, Bellomo, Sara Erika, primary, Corso, Simona, primary, Raimondi, Alessandra, primary, Berrino, Enrico, primary, Morano, Federica, primary, Migliore, Cristina, primary, Niger, Monica, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella Maria, primary, Marchiò, Caterina, primary, Di Bartolomeo, Maria, primary, Restuccia, Eleonora, primary, Lambertini, Chiara, primary, Tabernero, Josep, primary, and Giordano, Silvia, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results